Ursodeoxycholsäure plus Bezafibrat bei PBC
暂无分享，去创建一个
[1] G. Hirschfield,et al. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. , 2017, Journal of hepatology.
[2] J. Reguła,et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.
[3] A. Burroughs,et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.
[4] G. Alexander,et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.
[5] O. Chazouilleres,et al. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. , 2011, Journal of hepatology.
[6] K. Kowdley,et al. Predicting outcome in primary biliary cirrhosis. , 2014, Annals of hepatology.